Principles of antibiotic therapy in severe infections: Optimizing the therapeutic approach by use of laboratory and clinical data

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 3, 2007, Pages

  Deresinski, Stan ^a,b,c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c SEQUOIA HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CANDIDA; CLOSTRIDIUM DIFFICILE; CRITICALLY ILL PATIENT; ENTEROBACTER; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS; SHOCK, SEPTIC;

EID: 34548490300     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519472     Document Type: Review

References (32)

1. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31(Suppl 4):S131-8.
2. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-12.
3. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles. Infect Dis Clin North Am 2004; 18:939-62.
4. Clec'h C, Timsit JF, de Lassence A, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30:1327-33.
5. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
6. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
7. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-74.
8. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
10. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
11. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007; 45(Suppl 3):S191-5 (in this supplement).
12. Deresinski S. Vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543-8.
13. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42(Suppl 1):S51-7.
14. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
15. Hidayat LK, Hsu D, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166:2138-44.
16. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
17. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33:1845-53.
18. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18:638-56.
19. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11.
20. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
21. Fox BC, Fish J, Zheng L, Maki DG. Prospective study of de-escalation of antimicrobial therapy in an ICU [abstract 217]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Arlington, VA: Infectious Diseases Society of America, 2004:73.
22. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
23. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 2004; 101:13285-90.
24. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 2005; 55: 6-9.
25. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006; 43(Suppl 2):S82-8.
26. Merz LR, Warren DK, Kollef MH, Fridkin SK, Fraser VJ. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections. Chest 2006; 130:1672-8.
27. Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006; 57:1197-204.
28. Zillich AJ, Sutherland JM, Wilson SJ, et al. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol 2006; 27:1088-95.
29. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings: 12 steps to prevent antimicrobial resistance among hospitalized adults. Available at: http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm. Accessed 7 February 2007.
30. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006; 43:971-8.
31. Girou E, Legrand P, Soing-Altrach S, et al. Association between hand hygiene compliance and methicillin-resistant Staphylococcus aureus prevalence in a French rehabilitation hospital. Infect Control Hosp Epidemiol 2006; 27:1128-30.
32. Sandri AM, Dalarosa MG, Ruschel DA, da Silva EL, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006; 27:185-7.